We previously identified seven peptides in serum that are associated with hypertensive disorders of pregnancy (HDP). However, the significance of these peptides in the general population is unknown. The aim of this study was to clarify the relationships of HDP-associated peptides with hypertension and other cardiovascular risks in adult men. We investigated the relationships of peptide levels with cardiovascular risk factors, including adiposity, blood pressure, blood lipids and glycemic status, in men (mean age: 46.4 years) who were receiving annual health checkups at their workplace. The concentrations of the abovementioned seven peptides in serum were measured simultaneously using a mass spectrometer. Among the seven peptides, only a peptide with m/z 2091 (P-2091) derived from fibrinogen-α showed a significant correlation with diastolic blood pressure (Spearman’s rank correlation coefficient [r], −0.446). Another peptide with m/z 2378 (P-2378) originating from complement component 4 showed a significant positive correlation with body mass index (r, 0.273) and a significant inverse correlation with HDL cholesterol (r, −0.336). In addition, a peptide with m/z 3156 (P-3156) derived from an inter-α-trypsin inhibitor showed significant inverse correlations with body mass index (r, −0.258) and triglycerides (r, −0.334). There was no significant correlation of the levels of any of the seven peptides with hemoglobin A1c. Among the seven peptides related to HDP, P-2091, P-2378 and P-3156 were inversely associated with diastolic blood pressure, HDL cholesterol and triglycerides, respectively. Therefore, these peptides are possible biomarkers for discriminating cardiovascular risk in a general population.
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376:631–44.
Naderi S, Tsai SA, Khandelwal A. Hypertensive disorders of pregnancy. Curr Atheroscler Rep. 2017;19:15.
Araki Y, Yanagida M. Hypertensive disorders of pregnancy: strategy to develop clinical peptide biomarkers for more accurate evaluation of the pathophysiological status of this syndrome. Adv Clin Chem. 2020;94:1–30.
Tanaka K, Tsugawa N, Kim YO, Sanuki N, Takeda U, Lee LJ. A new rapid and comprehensive peptidome analysis by one-step direct transfer technology for 1-D electrophoresis/MALDI mass spectrometry. Biochem Biophys Res Commun. 2009;379:110–4.
Araki Y, Nonaka D, Tajima A, Maruyama M, Nitto T, Ishikawa H, et al. Quantitative peptidomic analysis by a newly developed one-step direct transfer technology without depletion of major blood proteins: its potential utility for monitoring of pathophysiological status in pregnancy-induced hypertension. Proteomics. 2011;11:2727–37.
Araki Y, Nonaka D, Hamamura K, Yanagida M, Ishikawa H, Banzai M, et al. Clinical peptidomic analysis by a one-step direct transfer technology: its potential utility for monitoring of pathophysiological status in female reproductive system disorders. J Obstet Gynaecol Res. 2013;39:1440–8.
Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in pregnancy: prevalence, risk factors, predictors and prognosis. Hypertens Res. 2017;40:213–20.
Benschop L, Duvekot JJ, Roeters, van Lennep JE. Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy. Heart. 2019;105:1273–8.
Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275:1571–6.
Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–32.
Kampoli AM, Tousoulis D, Antoniades C, Siasos G, Stefanadis C. Biomarkers of premature atherosclerosis. Trends Mol Med. 2009;15:323–32.
Hamamura K, Nonaka D, Ishikawa H, Banzai M, Yanagida M, Nojima M, et al. Simple quantitation for potential serum disease biomarker peptides, primarily identified by a peptidomics approach in the serum with hypertensive disorders of pregnancy. Ann Clin Biochem. 2016;53:85–96.
Hamamura K, Yanagida M, Ishikawa H, Banzai M, Yoshitake H, Nonaka D, et al. Quantitative measurement of a candidate serum biomarker peptide derived from α2-HS-glycoprotein, and a preliminary trial of multidimensional peptide analysis in females with pregnancy-induced hypertension. Ann Clin Biochem. 2018;55:287–95.
Yanagida M, Hamamura K, Takamori K, Araki Y. The simultaneous quantification of candidate serum biomarker peptides for hypertensive disorders of pregnancy. Ann Clin Biochem. 2019;56:457–65.
Anonymous. Metabolic syndrome-definition and diagnostic criteria in Japan. J Jpn Soc Int Med. 2005;94:794–809.
Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, et al. Committee on the standardization of diabetes mellitus-related laboratory testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Investig. 2012;3:39–40.
Wakabayashi I, Daimon T. The “cardiometabolic index” as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus. Clin Chim Acta. 2015;438:274–8.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.
Hsieh SD, Muto T. Metabolic syndrome in Japanese men and women with special reference to the anthropometric criteria for the assessment of obesity: Proposal to use the waist-to-height ratio. Prev Med. 2006;42:135–9.
Flack JM, Adekola B. Blood pressure and the new ACC/AHA hypertension guidelines. Trends Cardiovasc Med. 2020;30:160–4.
Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Japan Atherosclerosis Society. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan −2012 version. J Atheroscler Thromb. 2013;20:517–23.
Anonymous; American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33:S62–9.
Musini VM, Wright JM. Factors affecting blood pressure variability: lessons learned from two systematic reviews of randomized controlled trials. PLoS ONE. 2009;4:e5673.
Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985;110:1100–7.
Gaziano JM, Hennekens CH, O’Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997;96:2520–5.
Cordero A, Laclaustra M, León M, Casasnovas JA, Grima A, Luengo E, et al. MESYAS registry investigators. Comparison of serum lipid values in subjects with and without the metabolic syndrome. Am J Cardiol. 2008;102:424–8.
Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol. 1997;17:1114–20.
Wakabayashi I, Marumo M, Kubota Y, Higashiyama A, Miyamoto Y, Okamura T. Cardiometabolic index as a useful discriminator for the risk of increased arterial stiffness. Clin Chim Acta. 2018;486:42–3.
Wakabayashi I, Sotoda Y, Hirooka S, Orita H. Association between cardiometabolic index and atherosclerotic progression in patients with peripheral arterial disease. Clin Chim Acta. 2015;446:231–6.
Copenhaver M, Yu CY, Hoffman RP. Complement components, C3 and C4, and the metabolic syndrome. Curr Diabetes Rev. 2019;15:44–8.
Copenhaver MM, Yu CY, Zhou D, Hoffman RP. Relationships of complement components C3 and C4 and their genetics to cardiometabolic risk in healthy, non-Hispanic white adolescents. Pediatr Res. 2020;87:88–94.
Fujita Y, Ezura Y, Emi M, Sato K, Takada D, Iino Y, et al. Hypercholesterolemia associated with splice-junction variation of inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) gene. J Hum Genet. 2004;49:24–8.
Malaud E, Piquer D, Merle D, Molina L, Guerrier L, Boschetti E, et al. Carotid atherosclerotic plaques: proteomics study after a low-abundance protein enrichment step. Electrophoresis. 2012;33:470–82.
Moore PK, Hussaini I, Bhardwaj R. Cardiovascular effects of fibrinopeptide B. J Pharm Pharmacol. 1988;40:558–61.
Sturge J, Carey N, Davies AH, Powell JT. Fibrin monomer and fibrinopeptide B act additively to increase DNA synthesis in smooth muscle cells cultured from human saphenous vein. J Vasc Surg. 2001;33:847–53.
Hajri T, Caceres L, Angamarca-Armijos V. The burden of hypertension in Ecuador: a systematic review and meta-analysis. J Hum Hypertens. 2021;35:389–97.
Hata Y, Nakajima K. Life-style and serum lipids and lipoproteins. J Atheroscler Thromb. 2000;7:177–97.
Stevenson JC, Tsiligiannis S, Panay N. Cardiovascular risk in perimenopausal women. Curr Vasc Pharmacol. 2019;17:591–4.
This work was supported by a Grant-in-Aid for Scientific Research (No. 21H03386) from the Japan Society for the Promotion of Science.
Conflict of interest
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Wakabayashi, I., Yanagida, M. & Araki, Y. Associations of cardiovascular risk with circulating peptides related to hypertensive disorders of pregnancy. Hypertens Res (2021). https://doi.org/10.1038/s41440-021-00747-6
- Cardiovascular risk
- Mass spectrometry
- Peptide biomarker